Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 4/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CFD | P00746 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL28056490 | 0.95 | PNMT (0.41) | PNMTAKR1B1IDO1MPOTAAR1 | |
| Hydrochloric Acid SCHEMBL4204405 | 0.95 | PNMT (0.41) | PNMTAKR1B1IDO1MPOTAAR1 | |
| Tetrahydrofuran SCHEMBL1045376 | 0.86 | CYP2A13 (0.42) | PNMTAKR1B1P2RX7 | |
| Bromide SCHEMBL11300757 | 0.79 | PNMT (0.60) | PNMTIDO1TAAR1P2RX7CYP1A2 | |
| SCHEMBL3069271 | 0.79 | PNMT (0.43) | PNMTAKR1B1IDO1MPOTAAR1 | |
| SCHEMBL559225 | 0.79 | PNMT (0.67) | PNMTAKR1B1IDO1MPOTAAR1 | |
| SCHEMBL28092079 | 0.79 | PNMT (0.43) | PNMTAKR1B1IDO1MPOTAAR1 | |
| SCHEMBL4411424 | 0.79 | PNMT (0.43) | PNMTAKR1B1IDO1MPOTAAR1 | |
| SCHEMBL17552713 | 0.79 | PNMT (0.43) | PNMTAKR1B1IDO1MPOTAAR1 | |
| Bromide SCHEMBL4312125 | 0.79 | TAAR1 (0.38) | AKR1B1IDO1MPOTAAR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112661698-A | Preparation method of elvitegravir | 浙江海森药业股份有限公司 | 2021-04-16 | — | — | CN | claimed |
| EP-2906529-A1 | A NEW PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR | Zentiva K.S. (CZ) | 2015-08-19 | — | — | EP | claimed |
| WO-2015003670-A1 | A NEW PROCESS FOR THE PREPARATION OF ELVITEGRAVIR | ZENTIVA, K.S. (CZ) | 2015-01-15 | — | — | WO | claimed |
| WO-2014056464-A1 | A NEW PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR | ZENTIVA, K.S. (CZ) | 2014-04-17 | — | — | WO | claimed |
| US-20250091995-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2025-03-20 | — | — | US | disclosed |
| EP-4299563-A2 | COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND | Japan Tobacco Inc. (JP) | 2024-01-03 | — | — | EP | disclosed |
| EP-3281939-B1 | COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-4059923-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | Japan Tobacco Inc. (JP) | 2022-09-21 | — | — | EP | disclosed |
| US-20220235009-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2022-07-28 | — | — | US | disclosed |
| CN-112661698-A | Preparation method of elvitegravir | 浙江海森药业股份有限公司 | 2021-04-16 | — | — | CN | disclosed |
| US-20200101061-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2020-04-02 | — | — | US | disclosed |
| US-20060030710-A1 | Stable crystal of 4-oxoquinoline compound | SHIONOGI & CO., LTD. (JP) | 2006-02-09 | — | — | US | disclosed |
| US-20060019906-A1 | Novel 4-oxoquinoline compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20050288326-A1 | Combination therapy | SHIONOGI & CO., LTD. (JP) | 2005-12-29 | — | — | US | disclosed |
| WO-2005112930-A1 | COMBINATIONS COMPRISING A 4-ISOQUINOLONE DERIVATIVE AND ANTI-HIV AGENTS | JAPAN TOBACCO INC. (JP) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005113508-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005113509-A1 | NOVEL 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2005-12-01 | — | — | WO | disclosed |
| US-20050239819-A1 | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1564210-A1 | 4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288326-A1 | Combination therapy | TYMP, TPMT, PNP | PNMT 12/4885AKR1B1 1103/4885IDO1 113/4885 |
| US-20250091995-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | KCNQ2, KCNQ1, KCNQ5 | PNMT 1626/4885AKR1B1 3542/4885IDO1 750/4885 |
| US-20200101061-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, CDKL4, IMPDH2 | PNMT 347/4885AKR1B1 2418/4885IDO1 230/4885 |
| US-20220235009-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | GRIN2D, KCNQ2, RCC1 | PNMT 1488/4885AKR1B1 4580/4885IDO1 1526/4885 |
| US-20060019906-A1 | Novel 4-oxoquinoline compound and use thereof as HIV integrase inhibitor | IMPDH1, PIP4K2B, IMPDH2 | PNMT 2063/4885AKR1B1 2676/4885IDO1 186/4885 |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | PNMT 305/4885AKR1B1 2493/4885IDO1 229/4885 |
| US-20050239819-A1 | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors | IMPDH1, IMPDH2, TYMP | PNMT 367/4885AKR1B1 2356/4885IDO1 188/4885 |
| US-20060030710-A1 | Stable crystal of 4-oxoquinoline compound | KCNQ2, RCC1, SFPQ | PNMT 1508/4885AKR1B1 4528/4885IDO1 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.